These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30931902)

  • 1. [Improving efficacy of cancer immunotherapy through targeting of macrophages].
    Peranzoni E; Donnadieu E
    Med Sci (Paris); 2019 Mar; 35(3):207-209. PubMed ID: 30931902
    [No Abstract]   [Full Text] [Related]  

  • 2. Are peptide vaccines viable in combination with other cancer immunotherapies?
    Ohtake J; Sasada T
    Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
    Tartour E
    Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy.
    Andersson P; Ostheimer C
    Front Immunol; 2019; 10():2083. PubMed ID: 31555290
    [No Abstract]   [Full Text] [Related]  

  • 8. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic immunotherapy: an emerging new modality for the treatment of cancer.
    Coffin RS
    Ann Oncol; 2016 Sep; 27(9):1805-8. PubMed ID: 27166292
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?
    Milano G
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):223-224. PubMed ID: 30980131
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody Therapies in Cancer.
    Wang S; Jia M
    Adv Exp Med Biol; 2016; 909():1-67. PubMed ID: 27240456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].
    Foughali R; Marie JC
    Med Sci (Paris); 2020 Jan; 36(1):77-79. PubMed ID: 32014103
    [No Abstract]   [Full Text] [Related]  

  • 13. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
    Nishida S; Sugiyama H
    Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.
    Ciccolini J; Barbolosi D; André N; Benzekry S; Barlesi F
    Ann Oncol; 2019 Nov; 30(11):1690-1691. PubMed ID: 31504149
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoantigens in the immuno-oncology space.
    Arlen PM
    Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy in colorectal cancer.
    Le DT
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):22-24. PubMed ID: 29741500
    [No Abstract]   [Full Text] [Related]  

  • 18. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
    Ries CH; Hoves S; Cannarile MA; Rüttinger D
    Curr Opin Pharmacol; 2015 Aug; 23():45-51. PubMed ID: 26051995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined GM-CSF treatment and M-CSF inhibition of tumor-associated macrophages induces dendritic cell-like signaling in vitro.
    Kitoh Y; Saio M; Gotoh N; Umemura N; Nonaka K; Bai J; Vizkeleti L; Torocsik D; Balazs M; Adany R; Takami T
    Int J Oncol; 2011 May; 38(5):1409-19. PubMed ID: 21373754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.